SEC Filings
State Street Reports 5.1% Cytokinetics Stake As Heart-Drug Label Decision Awaits FDA
The passive holding covers 7,143,229 shares; Cytokinetics awaits a decision on adding comparative trial results to Myqorzo's label.
Cytokinetics (CYTK) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The passive holding covers 7,143,229 shares; Cytokinetics awaits a decision on adding comparative trial results to Myqorzo's label.
Earnings
Third-quarter myCORSO sales reached $44.5 million, and executives defended the drug's echo-monitoring rules against a rival's lighter trial design.